{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:29:44Z","timestamp":1794018584557,"version":"4.8.0"},"reference-count":34,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"\n Importance<\/jats:title>\n Gastric cancer with peritoneal metastasis has a poor prognosis, and survival with commonly used regimens, such as intravenous paclitaxel plus S-1 (an oral fluoropyrimidine), remains limited. Whether intraperitoneal paclitaxel, which achieves high drug concentrations in the peritoneal cavity, can improve survival has not been established in a phase 3 randomized clinical trial.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine whether adding intraperitoneal paclitaxel to intravenous paclitaxel plus S-1 improves overall survival in gastric cancer with peritoneal metastasis.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This multicenter, open-label, randomized phase 3 superiority clinical trial (DRAGON-01) was conducted in 9 hospitals in China. Enrollment went from May 2017 to March 2022, and the data cutoff was March 11, 2025. The trial included adults with gastric adenocarcinoma and laparoscopically confirmed peritoneal metastasis without extraperitoneal metastases or prior systemic therapy.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n \n The IP group received paclitaxel, 50 mg\/m\n 2<\/jats:sup>\n , intravenously plus 20 mg\/m\n 2<\/jats:sup>\n , intraperitoneally on days 1 and 8 of each 21-day cycle, with oral S-1, 80 mg\/m\n 2<\/jats:sup>\n , once per day on days 1 to 14. The PS group received paclitaxel, 70 mg\/m\n 2<\/jats:sup>\n , intravenously on days 1 and 8, with S-1 80, mg\/m\n 2<\/jats:sup>\n , once per day on days 1 to 14.\n <\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary end point was overall survival. Secondary end points included progression-free survival and safety.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among 222 treated patients (median [IQR] age, 59 [48-66] years; 104 [46.8%] female individuals and 118 [53.2%] male individuals), median (IQR) follow-up was 72.2 (50.8-80.2) months. Of 246 who were assessed, 238 (96.7%) were randomized 2:1 to receive intraperitoneal and intravenous paclitaxel plus oral S-1 (IP group) or intravenous paclitaxel plus S-1 (PS group); 222 (90.2%) received treatment (primary analysis). Median overall survival was 19.4 months (95% CI, 17.1-22.9) in the IP group and 13.9 months (95% CI, 10.3-16.1) in the PS group (hazard ratio, 0.67; 95% CI, 0.50-0.90;\n P<\/jats:italic>\n \u2009=\u2009.01). Median progression-free survival was 11.2 months (95% CI, 9.3-14.0) vs 7.2 months (95% CI, 5.7-11.6) (hazard ratio, 0.72; 95% CI, 0.54-0.96). Grade 3 or 4 adverse events occurred in 57 (38.5%) in the IP group and 31 (41.9%) in the PS group; no treatment-related deaths occurred.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n The results of this randomized clinical trial of patients with gastric cancer with peritoneal metastasis suggest that adding intraperitoneal paclitaxel to intravenous paclitaxel plus S-1 significantly improved overall survival without increasing severe toxic effects, potentially providing an encouraging signal for IP therapy in first-line treatment of gastric cancer with peritoneal metastasis.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n chictr.org.cn Identifier: ChiCTR-IIR-16009802<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaoncol.2026.1347","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:00:32Z","timestamp":1779375632000},"page":"732","source":"Crossref","is-referenced-by-count":13,"title":["Intraperitoneal and Intravenous Paclitaxel Plus S-1 for Gastric Cancer With Peritoneal Metastasis"],"prefix":"10.1001","volume":"12","author":[{"given":"Chao","family":"Yan","sequence":"first","affiliation":[{"name":"Department of General Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongyin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, The First Affiliated Hospital of Naval Medical University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Nie","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, The First Affiliated Hospital of Naval Medical University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Mou","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Pancreatic Surgery, Zhejiang Provincial People\u2019s Hospital, and Key Laboratory of Gastroenterology of Zhejiang Province, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunyun","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Pancreatic Surgery, Zhejiang Provincial People\u2019s Hospital, and Key Laboratory of Gastroenterology of Zhejiang Province, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastric Surgery, Fudan University Shanghai Cancer Center, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Gastric Surgery, Fudan University Shanghai Cancer Center, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiren","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Shandong Cancer Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinchun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal and Anal Surgery, The Affiliated Hangzhou First People\u2019s Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, The First Affiliated Hospital of Naval Medical University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenggang","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"coi260021r1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"coi260021r2","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ejso.2022.08.023","article-title":"Clinical epidemiology of peritoneal metastases in China: the construction of professional peritoneal metastases treatment centers based on the prevalence rate.","volume":"49","author":"Yang","year":"2023","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"coi260021r3","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1046\/j.1365-2168.2000.01360.x","article-title":"Recurrence following curative resection for gastric carcinoma.","volume":"87","author":"Yoo","year":"2000","journal-title":"Br J Surg"},{"issue":"3","key":"coi260021r4","doi-asserted-by":"publisher","first-page":"570","DOI":"10.3390\/cancers14030570","article-title":"Review of regional therapies for gastric cancer with peritoneal metastases.","volume":"14","author":"Sun","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"coi260021r5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cac2.12516","article-title":"The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2023.","volume":"44","author":"Wang","year":"2024","journal-title":"Cancer Commun (Lond)"},{"issue":"10","key":"coi260021r6","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up.","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"issue":"2","key":"coi260021r7","doi-asserted-by":"publisher","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","article-title":"Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology.","volume":"20","author":"Ajani","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"coi260021r8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-022-01331-8","article-title":"Japanese gastric cancer treatment guidelines 2021 (6th edition).","volume":"26","author":"Japanese Gastric Cancer Association","year":"2023","journal-title":"Gastric Cancer"},{"issue":"3","key":"coi260021r9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","article-title":"S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.","volume":"9","author":"Koizumi","year":"2008","journal-title":"Lancet Oncol"},{"issue":"19","key":"coi260021r10","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","article-title":"Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial.","volume":"36","author":"Ishigami","year":"2018","journal-title":"J Clin Oncol"},{"key":"coi260021r11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.905922","article-title":"Efficacy and safety of conversion therapy by intraperitoneal and intravenous paclitaxel plus oral S-1 in gastric cancer patients with peritoneal metastasis: a prospective phase II study.","volume":"12","author":"Yang","year":"2022","journal-title":"Front Oncol"},{"issue":"2","key":"coi260021r12","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/ags3.12060","article-title":"Treatment of patients with peritoneal metastases from gastric cancer.","volume":"2","author":"Kitayama","year":"2018","journal-title":"Ann Gastroenterol Surg"},{"issue":"S1","key":"coi260021r13","doi-asserted-by":"publisher","first-page":"S231","DOI":"10.21037\/jgo-2020-03","article-title":"Intraperitoneal paclitaxel: pharmacology, clinical results and future prospects.","volume":"12","author":"Sugarbaker","year":"2021","journal-title":"J Gastrointest Oncol"},{"issue":"2","key":"coi260021r14","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s10120-023-01452-8","article-title":"Oncological outcomes of conversion therapy in gastric cancer patients with peritoneal metastasis: a large-scale retrospective cohort study.","volume":"27","author":"Yang","year":"2024","journal-title":"Gastric Cancer"},{"issue":"4","key":"coi260021r15","doi-asserted-by":"publisher","first-page":"266","DOI":"10.5230\/jgc.2014.14.4.266","article-title":"The result of conversion surgery in gastric cancer patients with peritoneal seeding.","volume":"14","author":"Kim","year":"2014","journal-title":"J Gastric Cancer"},{"issue":"12","key":"coi260021r16","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1245\/s10434-009-0706-z","article-title":"Induction chemotherapy with S-1 plus cisplatin followed by surgery for treatment of gastric cancer with peritoneal dissemination.","volume":"16","author":"Okabe","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"coi260021r17","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s10120-016-0660-y","article-title":"Intraperitoneal chemotherapy for gastric cancer with peritoneal disease: experience from Singapore and Japan.","volume":"20","author":"Kono","year":"2017","journal-title":"Gastric Cancer"},{"issue":"7","key":"coi260021r18","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1245\/s10434-020-09388-4","article-title":"Intraperitoneal administration of paclitaxel combined with S-1 plus oxaliplatin as induction therapy for patients with advanced gastric cancer with peritoneal metastases.","volume":"28","author":"Saito","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"coi260021r19","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1245\/s10434-023-14240-6","article-title":"Phase II study of intraperitoneal administration of paclitaxel combined with S-1 and cisplatin for gastric cancer with peritoneal metastasis.","volume":"31","author":"Kobayashi","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"13","key":"coi260021r20","doi-asserted-by":"publisher","first-page":"8597","DOI":"10.1245\/s10434-022-11998-z","article-title":"Outcomes of a phase II study of intraperitoneal paclitaxel plus systemic capecitabine and oxaliplatin (XELOX) for gastric cancer with peritoneal metastases.","volume":"29","author":"Chia","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"coi260021r21","doi-asserted-by":"publisher","first-page":"5084","DOI":"10.1245\/s10434-022-11582-5","article-title":"Safety and efficacy of intraperitoneal paclitaxel plus intravenous fluorouracil, leucovorin, and oxaliplatin (FOLFOX) for gastric cancer with peritoneal metastasis.","volume":"29","author":"Kang","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"coi260021r22","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1007\/s10120-025-01653-3","article-title":"Eligibility criteria in phase 3 randomized controlled trials in gastric cancer.","volume":"28","author":"Marcisz-Grzanka","year":"2025","journal-title":"Gastric Cancer"},{"issue":"1","key":"coi260021r23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cct.2005.08.003","article-title":"The use of unequal randomisation ratios in clinical trials: a review.","volume":"27","author":"Dumville","year":"2006","journal-title":"Contemp Clin Trials"},{"issue":"2","key":"coi260021r24","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10120-011-0041-5","article-title":"Japanese classification of gastric carcinoma: 3rd English edition.","volume":"14","author":"Japanese Gastric Cancer Association","year":"2011","journal-title":"Gastric Cancer"},{"key":"coi260021r25","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5","article-title":"Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis.","volume":"82","author":"Jacquet","year":"1996","journal-title":"Cancer Treat Res"},{"issue":"7","key":"coi260021r26","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/cncr.11660","article-title":"Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy.","volume":"98","author":"Becker","year":"2003","journal-title":"Cancer"},{"issue":"2","key":"coi260021r28","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey.","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"issue":"1","key":"coi260021r29","first-page":"1","article-title":"Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.","volume":"62","author":"Dedrick","year":"1978","journal-title":"Cancer Treat Rep"},{"issue":"1","key":"coi260021r30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-012-0163-4","article-title":"Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry.","volume":"16","author":"Nashimoto","year":"2013","journal-title":"Gastric Cancer"},{"issue":"1","key":"coi260021r31","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40880-019-0349-9","article-title":"The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer.","volume":"39","author":"Wang","year":"2019","journal-title":"Cancer Commun (Lond)"},{"key":"coi260021r32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078876","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial.","volume":"385","author":"Qiu","year":"2024","journal-title":"BMJ"},{"key":"coi260021r33","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1200\/JCO.2025.43.4_suppl.398","article-title":"Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer\/gastroesophageal junction cancer\/esophageal adenocarcinoma (GC\/GEJC\/EAC): 5-year (y) follow-up results from CheckMate 649.","volume":"43","author":"Janjigian","year":"2025","journal-title":"J Clin Oncol"},{"key":"coi260021r34","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103731","article-title":"Intraperitoneal and intravenous paclitaxel plus S-1 and sintilimab as first-line treatment for gastric cancer with peritoneal metastasis: a single-arm phase 2 trial (DRAGON-09).","volume":"91","author":"Yuan","year":"2025","journal-title":"EClinicalMedicine"},{"key":"coi260021r27","unstructured":"US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Accessed April 20, 206. https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2849433\/jamaoncology_yan_2026_oi_260021_1784081561.28895.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T15:00:32Z","timestamp":1784214032000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2849433"}},"subtitle":["A Phase 3 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2026.1347","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}